immunohistochemistry kit can detect over 200 different protein biomarkers in clinical pathological diagnosis, among which tumor diagnosis-related markers account for approximately 75%. For instance, the accuracy rate of estrogen receptor (ER) and progesterone receptor (PR) tests in the diagnosis of breast cancer reaches 98%. Each year, approximately 1.8 million breast cancer patients worldwide undergo receptor status assessment through immunohistochemical kits. The human epidermal growth factor receptor 2 (HER2) detection kit can complete tissue section analysis within 4 hours through DAB coloration, with a specificity as high as 99.5%, significantly reducing the risk of misuse in trastuzumab treatment. According to the research data from the 2023 Journal of Clinical Pathology, the use of standardized immunohistochemical kits can increase the inter-laboratory consistency of HER2 detection from 68% to 94%.
In the field of neuropathology, the diagnostic accuracy rate of tau protein and β -amyloid protein detection kits for Alzheimer’s disease exceeds 92%. A multicenter study covering 5,000 samples showed that the sensitivity of using the AT8 antibody kit to detect phosphorylated tau protein reached 95.3% and the specificity reached 97.6%. Immunohistochemical kits for synuclein can detect Lewy bodies in the brain tissues of patients with Parkinson’s disease, with a detection limit of up to 0.1μg/mL tissue homogenate. The 2024 annual report of the Neurology Society shows that the standardized α -synuclein detection kits have increased diagnostic consistency to 89%.
In the detection of infectious diseases, the HPV L1 protein detection kit can locate virus particles through nuclear colorimetry, and its coincidence rate with PCR test results reaches 93.7%. The diagnostic sensitivity of the Epstein-Barr virus encoded small RNA (EBER) detection kit for nasopharyngeal carcinoma is 99.1%, and approximately 400,000 clinical tests apply this technology each year. Autopsy studies on COVID-19 have shown that the Spike protein-specific immunohistochemical kit can accurately track the virus distribution in lung tissue, and the correlation coefficient between viral load detection and RT-PCR results reaches 0.89.
In the detection of immune cell markers, kits such as CD3, CD20, and CD68 can precisely distinguish lymphocyte subsets and achieve a classification accuracy rate of over 95% in the diagnosis of lymphoma typing. The companion diagnosis of the PD-L1 detection kit has increased the accuracy rate of predicting the efficacy of immunosuppressants to 82%. According to the 2023 report of the Society for Tumor Immunotherapy, the overall response rate of patients using the 22C3 pharmDx kit has increased by 35%. The newly developed multiplex fluorescence immunohistochemical kit can simultaneously detect six biomarkers, increasing the throughput of tissue analysis by 400% and saving approximately 200 yuan in reagent costs for each sample.
With the development of automation technology, modern immunohistochemical kits can process up to 500 samples per day in large pathology departments, reducing manual operation time by 70%. Among the seven companion diagnostic kits approved by the FDA in 2024, five are based on immunohistochemistry kit technology, and the consistency of their test results with gene sequencing exceeds 90%. It is worth noting that the optimized immunohistochemical kit can reduce the antibody usage by 50%, while keeping the standard deviation of staining intensity within 0.15, significantly enhancing the accuracy of quantitative analysis.